P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention

D Capodanno, U Baber, DL Bhatt, JP Collet… - Nature Reviews …, 2022 - nature.com
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …

Sex differences in antiplatelet therapy: state-of-the art

A Gasecka, JM Zimodro, Y Appelman - Platelets, 2023 - Taylor & Francis
Antiplatelet therapy is a cornerstone of secondary prevention of cardiovascular diseases
(CVDs). However, current guidelines are based on data derived primarily from men, as …

Abbreviated or standard dual antiplatelet therapy by sex in patients at high bleeding risk: a prespecified secondary analysis of a randomized clinical trial

A Landi, M Alasnag, D Heg, E Frigoli, FTN Malik… - JAMA …, 2024 - jamanetwork.com
Importance Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …

Sex differences in therapies against myocardial ischemia-reperfusion injury: from basic science to clinical perspectives

L Medzikovic, T Azem, W Sun, P Rejali, L Esdin… - Cells, 2023 - mdpi.com
Mortality from myocardial infarction (MI) has declined over recent decades, which could be
attributed in large part to improved treatment methods. Early reperfusion is the cornerstone …

Advancing the access to cardiovascular diagnosis and treatment among women with cardiovascular disease: a joint British Cardiovascular Societies' consensus …

U Tayal, G Pompei, I Wilkinson, D Adamson, A Sinha… - Heart, 2024 - heart.bmj.com
Despite significant progress in cardiovascular pharmacotherapy and interventional
strategies, cardiovascular disease (CVD), in particular ischaemic heart disease, remains the …

The Signaling Pathway of the ADP Receptor P2Y12 in the Immune System: Recent Discoveries and New Challenges

P Entsie, Y Kang, EB Amoafo, T Schöneberg… - International Journal of …, 2023 - mdpi.com
P2Y12 is a G-protein-coupled receptor that is activated upon ADP binding. Considering its
well-established role in platelet activation, blocking P2Y12 has been used as a therapeutic …

Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis

TA Agbaedeng, JJ Noubiap, KA Roberts, DP Chew… - Drugs, 2024 - Springer
Background Although dual antiplatelet therapy (DAPT) improves the outcomes of patients
undergoing percutaneous coronary intervention (PCI), sex-specific differences in efficacy …

Bleeding and ischemic risks of ticagrelor monotherapy after coronary interventions

G Mendieta, S Mehta, U Baber, DJ Angiolillo… - Journal of the American …, 2023 - jacc.org
Abstract Background In TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients
After Coronary Intervention), among high-risk patients undergoing percutaneous coronary …

Platelet P2Y12 signalling pathway in the dysregulated immune response during sepsis

EB Amoafo, P Entsie, Y Kang… - British Journal of …, 2024 - Wiley Online Library
Sepsis is a complicated pathological condition in response to severe infection. It is
characterized by a strong systemic inflammatory response, where multiple components of …

[HTML][HTML] Secondary prevention of cardiovascular disease in women: closing the gap

A Thakkar, A Agarwala, ED Michos - European Cardiology Review, 2021 - ncbi.nlm.nih.gov
Cardiovascular disease (CVD) remains the leading cause of death in women globally.
Younger women (< 55 years of age) who experience MI are less likely to receive guideline …